228 related articles for article (PubMed ID: 28914199)
21. Advances in the use of IVIg in neurological disorders.
Hughes R
J Neurol; 2008 Jul; 255 Suppl 3():1-2. PubMed ID: 18685918
[No Abstract] [Full Text] [Related]
22. Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.
Wong PH; White KM
Clin Rev Allergy Immunol; 2016 Dec; 51(3):303-314. PubMed ID: 26142065
[TBL] [Abstract][Full Text] [Related]
23. Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry.
Stangel M; Baumann U; Borte M; Fasshauer M; Hensel M; Huscher D; Kirch W; Pittrow D; Reiser M; Gold R
J Clin Immunol; 2013 Jan; 33 Suppl 1():S67-71. PubMed ID: 22976553
[TBL] [Abstract][Full Text] [Related]
24. [The use of intravenous immunglobulin in the treatment of autoimmune neuromuscular diseases].
Molnár MJ
Ideggyogy Sz; 2006 Mar; 59(3-4):98-106. PubMed ID: 16634454
[TBL] [Abstract][Full Text] [Related]
25. [Anti-NMDA receptor encephalitis: two paediatric cases].
González-Toro MC; Jadraque-Rodríguez R; Sempere-Pérez Á; Martínez-Pastor P; Jover-Cerdá J; Gómez-Gosálvez F
Rev Neurol; 2013 Dec; 57(11):504-8. PubMed ID: 24265144
[TBL] [Abstract][Full Text] [Related]
26. Use of intravenous immunoglobulin and plasma exchange in neurological disease.
Linker RA; Gold R
Curr Opin Neurol; 2008 Jun; 21(3):358-65. PubMed ID: 18451723
[TBL] [Abstract][Full Text] [Related]
27. Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.
Lünemann JD; Nimmerjahn F; Dalakas MC
Nat Rev Neurol; 2015 Feb; 11(2):80-9. PubMed ID: 25561275
[TBL] [Abstract][Full Text] [Related]
28. A neurologist's guide to safe use of immunomodulatory therapies.
Vodopivec I; Miloslavsky EM; Kotton CN; Cho TA
Semin Neurol; 2014 Sep; 34(4):467-78. PubMed ID: 25369442
[TBL] [Abstract][Full Text] [Related]
29. Pharmacoresistent Partial Epilepsy Secondary to Progressive Inflammatory Poliodystrophy.
Kuperman RA; Martin KW
Pediatr Neurol; 2015 Jul; 53(1):83-7. PubMed ID: 25937386
[TBL] [Abstract][Full Text] [Related]
30. Inflammation, ictogenesis, and epileptogenesis: An exploration through human disease.
Tan TH; Perucca P; O'Brien TJ; Kwan P; Monif M
Epilepsia; 2021 Feb; 62(2):303-324. PubMed ID: 33316111
[TBL] [Abstract][Full Text] [Related]
31. Parry-Romberg syndrome and Rasmussen encephalitis: possible association. Clinical and neuroimaging features.
Longo D; Paonessa A; Specchio N; Delfino LN; Claps D; Fusco L; Randisi F; Genovese E; Vigevano F; Fariello G
J Neuroimaging; 2011 Apr; 21(2):188-93. PubMed ID: 19555404
[TBL] [Abstract][Full Text] [Related]
32. [High-dose intravenous immunoglobulin treatment].
Taneichi H; Miyawaki T
Nihon Rinsho; 2011 Mar; 69(3):515-9. PubMed ID: 21400848
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory therapies in neurologic critical care.
McDaneld LM; Fields JD; Bourdette DN; Bhardwaj A
Neurocrit Care; 2010 Feb; 12(1):132-43. PubMed ID: 19774497
[TBL] [Abstract][Full Text] [Related]
34. [Autoimmune encephalitis, clinical, radiological and immunological data].
Aupy J; Collongues N; Blanc F; Tranchant C; Hirsch E; De Seze J
Rev Neurol (Paris); 2013 Feb; 169(2):142-53. PubMed ID: 23099105
[TBL] [Abstract][Full Text] [Related]
35. The recognition and treatment of autoimmune epilepsy in children.
Suleiman J; Dale RC
Dev Med Child Neurol; 2015 May; 57(5):431-40. PubMed ID: 25483277
[TBL] [Abstract][Full Text] [Related]
36. Rasmussen encephalitis with active inflammation and delayed seizures onset.
Korn-Lubetzki I; Bien CG; Bauer J; Gomori M; Wiendl H; Trajo L; Ovadia H; Wilken B; Hans VH; Elger CE; Hurvitz H; Steiner I
Neurology; 2004 Mar; 62(6):984-6. PubMed ID: 15037707
[TBL] [Abstract][Full Text] [Related]
37. Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
Bascić-Kes V; Kes P; Zavoreo I; Lisak M; Zadro L; Corić L; Demarin V;
Acta Clin Croat; 2012 Dec; 51(4):673-83. PubMed ID: 23540178
[TBL] [Abstract][Full Text] [Related]
38. Long-term effect of rituximab in a case with late-onset Rasmussen´s encephalitis with anti-ganglioside IgGQ1b and anti-GAD antibodies positivity. Case Report.
Timarova G; Lisa I; Kukumberg P
Neuro Endocrinol Lett; 2016 Jul; 37(3):179-183. PubMed ID: 27618602
[TBL] [Abstract][Full Text] [Related]
39. Breaking the cycle: A comparison between intravenous immunoglobulins and high dosage prednisone in the treatment of medically intractable epilepsy in children.
Tang-Wai R; Mailo J; Rosenblatt B
Seizure; 2017 Apr; 47():34-41. PubMed ID: 28284046
[TBL] [Abstract][Full Text] [Related]
40. Immunoglobulin therapy in neurologic diseases.
Berlit P
Klin Wochenschr; 1989 Oct; 67(19):967-70. PubMed ID: 2693819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
